Acromegaly pathogenesis and treatment
Top Cited Papers
Open Access
- 2 November 2009
- journal article
- review article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 119 (11), 3189-3202
- https://doi.org/10.1172/jci39375
Abstract
Dysregulated growth hormone (GH) hypersecretion is usually caused by a GH-secreting pituitary adenoma and leads to acromegaly — a disorder of disproportionate skeletal, tissue, and organ growth. High GH and IGF1 levels lead to comorbidities including arthritis, facial changes, prognathism, and glucose intolerance. If the condition is untreated, enhanced mortality due to cardiovascular, cerebrovascular, and pulmonary dysfunction is associated with a 30% decrease in life span. This Review discusses acromegaly pathogenesis and management options. The latter include surgery, radiation, and use of novel medications. Somatostatin receptor (SSTR) ligands inhibit GH release, control tumor growth, and attenuate peripheral GH action, while GH receptor antagonists block GH action and effectively lower IGF1 levels. Novel peptides, including SSTR ligands, exhibiting polyreceptor subtype affinities and chimeric dopaminergic-somatostatinergic properties are currently in clinical trials. Effective control of GH and IGF1 hypersecretion and ablation or stabilization of the pituitary tumor mass lead to improved comorbidities and lowering of mortality rates for this hormonal disorder.Keywords
This publication has 138 references indexed in Scilit:
- Liver-specific Deletion of the Growth Hormone Receptor Reveals Essential Role of Growth Hormone Signaling in Hepatic Lipid MetabolismJournal of Biological Chemistry, 2009
- Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1aProceedings of the National Academy of Sciences, 2008
- p21 Cip1 restrains pituitary tumor growthProceedings of the National Academy of Sciences of the United States of America, 2008
- Epithelial Sodium Channel Is a Key Mediator of Growth Hormone-Induced Sodium Retention in AcromegalyEndocrinology, 2008
- A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegalyClinical Endocrinology, 2007
- Long‐term (up to 18 years) effects on GH/IGF‐1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH‐secreting pituitary adenoma responsive to SSTaClinical Endocrinology, 2007
- Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutationsProceedings of the National Academy of Sciences of the United States of America, 2007
- p18Ink4c, but Not p27Kip1, Collaborates with Men1 To Suppress Neuroendocrine Organ TumorsMolecular and Cellular Biology, 2007
- Germ-line mutations in p27
Kip1
cause a multiple endocrine neoplasia syndrome in rats and humansProceedings of the National Academy of Sciences, 2006
- Model for growth hormone receptor activation based on subunit rotation within a receptor dimerNature Structural & Molecular Biology, 2005